(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of the 2010 Warrants (as defined below) by eighteen months, from August 5, 2013 at 5:00 p.m. (Toronto time) (the …
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (the “Company” or “Helix”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that it has initiated the process of changing Helix’s auditor from KPMG LLP (“KPMG”) to BDO Canada LLP (“BDO”). The change will be effective as of the completion of the audit for …
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of Stace Wills to the board of directors. Mr. Wills is a resident Canadian and his appointment was effective June 12, 2013. Commenting on the appointment, Mario Gobbo, Chairman of the Board of Helix, …
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the fourth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle …
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that Helix’s Chief Science Officer, Dr. Heman Chao, will be presenting a scientific poster at American Association for Cancer Research (AACR) Annual Meeting in Washington, DC on Tuesday April 9, 2013. Dr. Chao’s poster, entitled, Development …
L-DOS47 Presentation at AACR 2013 Annual Meeting
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the third dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle …
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that Helix’s Chief Science Officer, Dr. Heman Chao, will be making a presentation relating to Helix’s L-DOS47 platform at BIT LifeScience’s 5th International Congress of Antibodies in Hangzhou, China on March 19, 2013. Dr. Chao’s presentation, …
L-DOS47 Presentation at the BIT’s 5th Annual International Congress of Antibiodies Conference March 2013
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results and research and development update for the three and six month periods ended January 31, 2013 and 2012. HIGHLIGHTS DURING THE FISCAL QUARTER ENDED JANUARY 31, 2013 On December 14, 2012 the Company …